CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence

(2016) C Yang et al.   ONCOGENE

Targeting the RB-E2F pathway in breast cancer

(2016) J Johnson et al.   ONCOGENE

Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer

(2015) Natalia J. Sumi et al.   ACS Chemical Biology

Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer

(2015) Yan Zhu et al.   BMC CANCER

Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment

(2015) T. VanArsdale et al.   CLINICAL CANCER RESEARCH

CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma

(2015) M. E. Olanich et al.   CLINICAL CANCER RESEARCH

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

(2015) Richard S Finn et al.   LANCET ONCOLOGY

Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas

(2015) S K A Divakar et al.   LEUKEMIA

Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer

(2015) Agnieszka K. Witkiewicz et al.   Oncotarget

Aging interventions get human

(2015) Brian K. Kennedy et al.   Oncotarget

CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer

(2015) Jorge Franco et al.   Oncotarget

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

(2014) Lawrence M. Gelbert et al.   INVESTIGATIONAL NEW DRUGS

The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation

(2014) V. Yadav et al.   MOLECULAR CANCER THERAPEUTICS

Antiproliferative Effects of CDK4/6 Inhibition in CDK4-Amplified Human Liposarcoma In Vitro and In Vivo

(2014) Y.-X. Zhang et al.   MOLECULAR CANCER THERAPEUTICS

Genomic and molecular characterization of esophageal squamous cell carcinoma

(2014) De-Chen Lin et al.   NATURE GENETICS

Esophageal Carcinoma

(2014) Anil K. Rustgi et al.   NEW ENGLAND JOURNAL OF MEDICINE

A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS

(2013) Xiang-Hua Zhang et al.   CANCER BIOLOGY & THERAPY

CDK4 inhibition restores G₁-S arrest inMYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage

(2013) Sina Gogolin et al.   CELL CYCLE

Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma

(2013) J. Rader et al.   CLINICAL CANCER RESEARCH

Structural Properties of Polyphenols Causing Cell Cycle Arrest at G1 Phase in HCT116 Human Colorectal Cancer Cell Lines

(2013) Soon Shin et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

(2012) J. P. Leonard et al.   BLOOD

CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy

(2012) A. Kathleen McClendon et al.   CELL CYCLE

Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy

(2012) Patrick J. Roberts et al.   JNCI-Journal of the National Cancer Institute

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS